50 Erectile Dysfunction Clinical Trials in San Antonio, TX (2026)

Q: How do I join a clinical trial in San Antonio?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Antonio research site will contact you.

Recruiting Erectile Dysfunction Studies in San Antonio

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

San Antonio, TXPHASE1695 participantsAstraZeneca

View Study Details

NCT06384352Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evalu...

San Antonio, TXPHASE1500 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05458219Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic s...

San Antonio, TXPHASE1470 participantsInnovent Biologics (Suzhou) Co. Ltd.

View Study Details

NCT07197827Recruiting

A Study of YL242 in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors....

San Antonio, TXPHASE1424 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

San Antonio, TXPHASE1416 participantsGilead Sciences

View Study Details

NCT06792552Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors...

San Antonio, TXPHASE1414 participantsNextCure, Inc.

View Study Details

NCT07122700Recruiting

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- a...

San Antonio, TX400 participantsFoundation for the National Institutes of Health

View Study Details

NCT07160725Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors...

San Antonio, TXPHASE1315 participantsBristol-Myers Squibb

View Study Details

NCT07136779Recruiting

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or...

San Antonio, TXPHASE1310 participantsVelaVigo Bio Inc

View Study Details

NCT06239194Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors....

San Antonio, TXPHASE1285 participantsModeX Therapeutics, An OPKO Health Company

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

San Antonio, TXPHASE1254 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

San Antonio, TXPHASE1245 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT06413680Recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

San Antonio, TXPHASE1240 participantsRegeneron Pharmaceuticals

View Study Details

NCT07141706Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up t...

San Antonio, TXPHASE1233 participantsDualityBio Inc.

View Study Details

NCT05985655Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors....

San Antonio, TXPHASE1230 participantsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

View Study Details

NCT06577987Recruiting

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors....

San Antonio, TXPHASE1220 participantsCircle Pharma

View Study Details

NCT07288359Recruiting

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical e...

San Antonio, TXPHASE1205 participantsNovartis Pharmaceuticals

View Study Details

NCT07527910Recruiting

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MA...

San Antonio, TXPHASE2204 participantsRegeneron Pharmaceuticals

View Study Details

NCT04219254Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1...

San Antonio, TXPHASE1197 participantsBioInvent International AB

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

San Antonio, TXPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT07128303Recruiting

Study of GS-5319 in Adults With Solid Tumors

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration ...

San Antonio, TXPHASE1178 participantsGilead Sciences

View Study Details

NCT07601243Recruiting

Study of GS-2426 in Participants With Advanced Solid Tumors

The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tum...

San Antonio, TXPHASE1174 participantsGilead Sciences

View Study Details

NCT07266428Recruiting

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects tha...

San Antonio, TXPHASE1170 participantsOttimo Pharma Limited

View Study Details

NCT05878795Recruiting

Written Exposure Therapy for Suicide Prevention

Military service members admitted to inpatient psychiatry for self-injurious thoughts and behaviors (SITBs) represent an at-risk group for continued SITBs and rehospitalizations in the post-discharge ...

San Antonio, TXNA160 participantsBoston University

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

San Antonio, TXPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT07124117Recruiting

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and putative recommended phase 2 dose of OBI-902 (study drug) as monotherapy. Part B (Cohort ...

San Antonio, TXPHASE1147 participantsOBI Pharma, Inc

View Study Details

NCT07605962Recruiting

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle....

San Antonio, TXPHASE1140 participantsUnited Immunity, co., Ltd.

View Study Details

NCT05784688Recruiting

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors....

San Antonio, TXPHASE1140 participantsTiumBio Co., Ltd.

View Study Details

NCT07360314Recruiting

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metas...

San Antonio, TXPHASE1138 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT07535112Recruiting

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS. Colorectal canc...

San Antonio, TXPHASE1130 participantsBayer

View Study Details

NCT05841563Recruiting

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - s...

San Antonio, TXPHASE1125 participantsPharmaMar

View Study Details

NCT05974631Recruiting

Evaluating Treatments for Suicidal Veterans With PTSD

Posttraumatic Stress Disorder (PTSD) is a significant driver of suicide risk among Veterans, but there is a critical knowledge gap about how to treat PTSD among people at elevated risk for suicide. Al...

San Antonio, TXNA125 participantsVA Office of Research and Development

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

San Antonio, TXPHASE1114 participantsIpsen

View Study Details

NCT07148128Recruiting

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours....

San Antonio, TXPHASE1110 participantsAuricula Biosciences Inc.

View Study Details

NCT06975293Recruiting

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalima...

San Antonio, TXPHASE1107 participantsSTORM Therapeutics LTD

View Study Details

NCT06399757Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus o...

San Antonio, TXPHASE1100 participantsApollo Therapeutics Ltd

View Study Details

NCT06799065Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and pr...

San Antonio, TXPHASE190 participantsAccent Therapeutics

View Study Details

NCT07414836Recruiting

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants...

San Antonio, TXPHASE184 participantsBeOne Medicines

View Study Details

NCT06730347Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be e...

San Antonio, TXPHASE280 participantsMacroGenics

View Study Details

NCT05417321Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors...

San Antonio, TXPHASE180 participantsShanghai Huaota Biopharmaceutical Co., Ltd.

View Study Details

NCT07166601Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looki...

San Antonio, TXPHASE177 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT04652882Recruiting

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD....

San Antonio, TXPHASE370 participantsVanda Pharmaceuticals

View Study Details

NCT07284420Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myas...

San Antonio, TXPHASE270 participantsargenx

View Study Details

NCT07115043Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors...

San Antonio, TXPHASE160 participantsAstraZeneca

View Study Details

NCT06959706Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pha...

San Antonio, TXPHASE150 participantsTagworks Pharmaceuticals BV

View Study Details

NCT07161414Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety...

San Antonio, TXPHASE140 participantsAstraZeneca

View Study Details

NCT04789044Recruiting

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is s...

San Antonio, TXPHASE240 participantsMajor Extremity Trauma Research Consortium

View Study Details

NCT06274788Recruiting

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this pat...

San Antonio, TX40 participantsFresenius Kabi

View Study Details

NCT06750185Recruiting

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 i...

San Antonio, TXPHASE139 participantsBioNTech SE

View Study Details

NCT04617522Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems....

San Antonio, TXPHASE130 participantsGilead Sciences

View Study Details

About Erectile Dysfunction Clinical Trials in San Antonio

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 50 erectile dysfunction clinical trials recruiting participants in San Antonio, TX. These studies are seeking a combined 9,500 participants. Research is being sponsored by AstraZeneca, MediLink Therapeutics (Suzhou) Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd. and 39 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in San Antonio — FAQ

Are there erectile dysfunction clinical trials in San Antonio?

Yes, there are 50 erectile dysfunction clinical trials currently recruiting in San Antonio, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Antonio?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Antonio research site will contact you about next steps.

Are clinical trials in San Antonio free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Antonio studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 50 active trials in San Antonio are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated July 22, 2026 from ClinicalTrials.gov